investors

Reports


 


Please contact CEO Dr. Mathias Svahn for an investor pack and other information.

mathias.svahn@nextcellpharma.com

Financial calendar

Interim Report


Q3 NextCell Pharma (released 31 July 2017)

Year-End Report


31 October 2017

Annual Report


31 October 2017

Annual General Meeting


Planned for December 2017

Share information

Dividend

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development. There is a risk that future cash flows will not exceed the company’s capital requirements and that future AGMs will not decide on future dividends.

Transparency

NextCell Pharma AB comply with the Market Abuse Regulation (2014/596/EU) .

Share price

Please visit AktieTorget for real time information

NextCell Pharma (NEXTCL)

List of owners (2017-05-31)

Owners

Number of shares

Ownership (%)

Diamyd Medical AB*

804 291

16.3

Anders Essen-Möller**

562 033

11.4

Bertil Lindkvist

444 652

9.0

Göran Ofsén

380 000

7.7

MabTech Group AB

291 216

5.9

Other owners

2 347 058

47.6

   
Total

4 929 250

100.0

 

* NextCell’s Board Chairman Anders Essen-Möller owns 16.8% of the shares and 40.1% of the votes in Diamyd Medical AB.

** Anders Essen-Möller is the Board Chairman of NextCell. 

Corporate governance

Nomination Committee


No information available

Auditor


Bo Åsell

Öhrlings PricewaterhouseCoopers AB (PwC)
Torsgatan 21, 113 97 Stockholm

Bo Åsell is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden.

Mathias-300x400-225x300

IR contact


Dr. Mathias Svahn, CEO
Phone: +46 (0)70 261 55 04
Email: mathias.svahn@nextcellpharma.com

AktieTorget

NextCell Pharma AB was listed on the AktieTorget 13th of July 2017.

Link to NextCell Pharma on AktieTorget